MedTrace Logo

Dose Range Finding Study of Fedovapagon in Men With Nocturia

NCT01656239 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 358

Last updated 2014-06-20

No results posted yet for this study

Summary

The purpose of this study is to determine the dose level(s) of fedovapagon which result in a decrease in the mean nocturnal void frequency.

Conditions

  • Nocturia

Interventions

DRUG

fedovapagon 1 mg

DRUG

fedovapagon 2 mg

DRUG

fedovapagon 4 mg

DRUG

Placebo ( sugar pill)

Sponsors & Collaborators

  • Vantia Ltd

    lead INDUSTRY

Principal Investigators

  • Hilary McElwaine-Johnn, BSc, ASM, MBBS, MRCP, MFPM · Vantia Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2013-08-31
Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01656239 on ClinicalTrials.gov